Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Roche (Switzerland) · Janssen (Belgium) · +16 more institutions
Abstract
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatments. Methods We performed a randomized trial to evaluate treatment adaptation on the basis of early PET (ePET) after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated-according to European Organisation for Research and Treatment of Cancer criteria favorable (F) and unfavorable (U)-stage I and II HL. The standard arm consisted of ABVD followed by involved-node radiotherapy (INRT), regardless of…
Citation impact
- FWCI
- 39.65
- Percentile
- 100%
- References
- 20
Authors
26- MAMarc André
Roche (Switzerland), Janssen (Belgium), Radboud University Nijmegen, Bayer (United States), Bristol-Myers Squibb (Germany), Radboud University Medical Center, Takeda (Ireland), Takeda (Italy), MSD K.K. (Japan), de Duve Institute, Servier (France), Gilead Sciences (United States), Gilead Sciences (Australia), Karyopharm Therapeutics (United States), Takeda (France), Takeda (Japan), Varian Medical Systems (United States), Bristol-Myers Squibb (Switzerland)
- TGT. Girinsky
Roche (Switzerland), Janssen (Belgium), Radboud University Nijmegen, Bayer (United States), Bristol-Myers Squibb (Germany), Radboud University Medical Center, Takeda (Ireland), Takeda (Italy), MSD K.K. (Japan), de Duve Institute, Servier (France), Gilead Sciences (United States), Gilead Sciences (Australia), Karyopharm Therapeutics (United States), Takeda (France), Takeda (Japan), Varian Medical Systems (United States), Bristol-Myers Squibb (Switzerland)
- MFMassimo Federico
Roche (Switzerland), Janssen (Belgium), Radboud University Nijmegen, Bayer (United States), Bristol-Myers Squibb (Germany), Radboud University Medical Center, Takeda (Ireland), Takeda (Italy), MSD K.K. (Japan), de Duve Institute, Servier (France), Gilead Sciences (United States), Gilead Sciences (Australia), Karyopharm Therapeutics (United States), Takeda (France), Takeda (Japan), Varian Medical Systems (United States), Bristol-Myers Squibb (Switzerland)
- OROumédaly Reman
Roche (Switzerland), Janssen (Belgium), Radboud University Nijmegen, Bayer (United States), Bristol-Myers Squibb (Germany), Radboud University Medical Center, Takeda (Ireland), Takeda (Italy), MSD K.K. (Japan), de Duve Institute, Servier (France), Gilead Sciences (United States), Gilead Sciences (Australia), Karyopharm Therapeutics (United States), Takeda (France), Takeda (Japan), Varian Medical Systems (United States), Bristol-Myers Squibb (Switzerland)
- CFCatherine Fortpied
Roche (Switzerland), Janssen (Belgium), Radboud University Nijmegen, Bayer (United States), Bristol-Myers Squibb (Germany), Radboud University Medical Center, Takeda (Ireland), Takeda (Italy), MSD K.K. (Japan), de Duve Institute, Servier (France), Gilead Sciences (United States), Gilead Sciences (Australia), Karyopharm Therapeutics (United States), Takeda (France), Takeda (Japan), Varian Medical Systems (United States), Bristol-Myers Squibb (Switzerland)
Topics & keywords
- Medicine
- Positron emission tomography
- Stage (stratigraphy)
- Lymphoma
- Nuclear medicine
- Randomized controlled trial
- Positron Emission Tomography-Computed Tomography
- Hodgkin lymphoma
- Good health and well-being